Jiang Wu is a director of clinical biomarker innovation and development at Takeda, responsible for implementing bioanalytical and biomarker strategy and developing, validating, and executing assays in support of clinical and in vitro diagnostics programs. Prior to Takeda, he was an associate research fellow at Pfizer-Wyeth where his team utilized a variety of protein mass spec techniques to identify and validate novel drug targets, biomarkers, and elucidate drug mechanism of actions to support drug discovery and translational medicine. Before joining Wyeth, he was a group leader of proteomic biomarker discovery at Millennium Pharmaceuticals and a senior scientist at Abbott Diagnostic Division. Jiang obtained his Ph.D in Analytical Biochemistry from Michigan State. He has broad experience in biotherapeutics characterization, chemical proteomics, and regulated bioanalysis, and is an author of 60+ scientific papers, book chapters, and patents.
Tuesday, October 27, 2020
3:30 PM – 3:45 PM ET